Attention MacroGenics Investors
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company dedicated to creating and selling innovative treatments, is currently facing an ongoing securities class action lawsuit. If you own or have owned shares of MacroGenics within a certain timeframe, it's important to be aware of this situation, as it may significantly affect your legal rights.
Understanding the Lawsuit
The lawsuit claims that MacroGenics provided misleading information regarding the interim safety data from their TAMARACK Phase 2 study. This study looked into a drug called vobramitamab duocarmazine, intended for treating prostate cancer. These misleading statements could have resulted in financial losses for investors who purchased shares in the company.
Your Rights as an Investor
If you bought shares of MacroGenics, particularly between March 7, 2024, and May 9, 2024, it’s essential to understand your rights. Consulting with legal experts can help clarify if you can be involved as a lead plaintiff in this lawsuit. A lead plaintiff represents the interests of other investors throughout the litigation process.
Key Deadlines
Investors should be aware of important deadlines tied to this lawsuit. If you're considering becoming a lead plaintiff, you must submit the required paperwork by September 24, 2024. Even if you decide not to take action, it’s crucial to know that you can still be part of the class action without losing your rights to any potential recovery.
How to Get Involved
If you feel affected by the recent developments surrounding MacroGenics, it's advisable to reach out to legal professionals. Many law firms, including Bernstein Liebhard LLP, offer contingency fee arrangements. This means investors won't incur upfront costs, making it easier for every shareholder to pursue justice.
Why Trust Bernstein Liebhard LLP?
Bernstein Liebhard LLP is a well-regarded law firm known for its strong track record in securities litigation. Since 1993, they've helped clients recover over $3.5 billion. Their commitment extends to both individual investors and large public and private pension funds, demonstrating their capability in achieving positive outcomes.
What to Expect Moving Forward
As the lawsuit develops, shareholders of MacroGenics, Inc. (NASDAQ: MGNX) should stay informed about any updates. Keeping an eye on the company’s communications and engaging with investor relations will provide vital information regarding the lawsuit and its potential effects on your investment. Staying connected with legal representatives is also important to understand your rights and responsibilities as part of the class action.
Frequently Asked Questions
1. What is the class action lawsuit against MacroGenics about?
The lawsuit claims that MacroGenics provided misleading information about the safety data linked to its prostate cancer treatment, resulting in financial losses for investors.
2. How do I know if I'm eligible to participate?
If you purchased shares of MacroGenics between March 7, 2024, and May 9, 2024, you might be eligible to take part in the lawsuit.
3. What is the deadline for filing paperwork?
The deadline to file as a lead plaintiff is September 24, 2024.
4. What are the costs involved in pursuing this lawsuit?
Bernstein Liebhard LLP operates on a contingency fee basis, meaning you won’t pay fees unless you recover funds.
5. How can I contact investor relations for more information?
You can reach out to Peter Allocco at (212) 951-2030 for assistance with your investments in MacroGenics, Inc.